Ototoxicity from cis-platinum in patients with Stages III and IV previously untreated squamous cell cancer of the head and neck*

Susan M. Fleming, V. Ratanatharathorn, Arthur Weaver, G. Peters, Sean B. Peppard, Marie Schumacher, Muhyi Al‐Sarraf

American Journal of Clinical Oncology · 1985 · 21 citations · 0 references

Concepts

Abstract

Forty-four patients were evaluated for ototoxicity following treatment with the chemotherapeutic agent cis-platinum. Statistically significant hearing changes at 2,000 Hz (p less than 0.001); 4,000 Hz (p less than 0.05); and 8,000 Hz (p less than 0.001) were observed. Chi-square analysis demonstrated that at 8,000 Hz patients who had lower than average thresholds prior to chemotherapy were more likely to experience greater threshold shift than those patients whose pre-chemotherapy thresholds were higher than average. In this patient sample, there was no significant correlation shown between serum creatinine levels and ototoxicity.